<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oral antibiotic therapy for small intestinal bacterial overgrowth (SIBO)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oral antibiotic therapy for small intestinal bacterial overgrowth (SIBO)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Oral antibiotic therapy for small intestinal bacterial overgrowth (SIBO)</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Antibiotic</td> <td class="subtitle1">Adult dose<sup>[1]</sup></td> <td class="subtitle1">Pediatric dose*<sup>[2,3]</sup></td> <td class="subtitle1">Notes</td> </tr> <tr class="divider_bottom"> <td>Rifaximin<sup>¶</sup></td> <td>550 mg three times daily</td> <td> <p>Children and adolescents ≥12 years: Refer to adult dosing</p> Children 3 to 11 years: 200 mg three times daily<sup>[4]</sup></td> <td> <p>Preferred by UpToDate author</p> <p>Efficacy 61 to 78%</p> <p>Low systemic absorption</p> High cost relative to other options</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Alternative antibiotics</td> </tr> <tr class="divider_bottom"> <td class="indent1">Trimethoprim-sulfamethoxazole (TMP-SMX)</td> <td>160/800 mg twice daily</td> <td>4 to 5 mg/kg of trimethoprim component per dose twice daily<sup>[5]</sup></td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Ciprofloxacin</td> <td>500 mg twice daily</td> <td>10 to 20 mg/kg per dose twice daily</td> <td>Routine use in children avoided due to potential risk of musculoskeletal toxicity (usually mild)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Amoxicillin-clavulanate</td> <td>875 mg twice per day</td> <td>25 to 30 mg/kg per day (amoxicillin component) in two or three divided doses</td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Metronidazole</td> <td>250 mg three times per day</td> <td>10 mg/kg per dose twice daily</td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Doxycycline</td> <td>100 mg once daily to twice per day</td> <td> <p>Children ≥8 years and &gt;45 kg: Refer to adult dosing</p> Children &lt;8 years: Not recommended</td> <td> <p>Less risk of dental staining in children with short course</p> Use and dosing extrapolated from data with tetracycline</td> </tr> <tr> <td class="indent1">Tetracycline</td> <td>250 mg four times per day</td> <td> <p>Children ≥8 years: 10 to 15 mg/kg per dose three times daily</p> Children &lt;8 years: Not recommended</td> <td>Use in children &lt;8 years old avoided due to risk of permanent tooth discoloration</td> </tr> </tbody></table></div><div class="graphic_lgnd">Suggested antibiotic regimens for reduction of gut flora overgrowth and symptomatic improvement. The author usually treats for 10 days per course with the exception of rifaximin a 14-day course is given. Doses listed are for patients with normal renal function. For indications and administration of antibiotic therapy in SIBO, refer to the UpToDate clinical topic review.</div><div class="graphic_footnotes">* Optimal antibiotic regimen(s) in children have not been established. Antimicrobial choices and doses shown are those used by the UpToDate author and some other experts when antibiotic therapy of SIBO is indicated in children<sup>[2,3]</sup>. The pediatric daily dose should not exceed the usual daily dose for adult patients. Pediatric doses listed in this table are for children ≥6 years except as noted.<br/>	

	¶ In patients with intestinal methane overgrowth (IMO) the author uses a combination regimen of oral rifaximin 550 mg three times daily with oral neomycin 500 mg twice daily for 14 days.</div><div class="graphic_reference">References: 

<ol>
<li>Pimentel M, Saad R, Long M, et al. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol 2020; 115:165.</li>
<li>Malik BA, Yuan XY, Wine E, Huynh HQ. Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. Can J Gastroenterol 2011; 25:41.</li>
<li>Avelar Rodriguez D, Ryan PM, Ramirez Mayans JA, Quigley EM. Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review. Frontiers in Pediatrics 2019; 7:363.</li>
<li>Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013; 17:1314.</li>
<li>Kimberlin DW, Brady MT, Jackson MA, Long SS. Dose based on usual range recommended for children. In: Red Book, 31st ed, Committee on Infectious Diseases (Ed); American Academy of Pediatrics, Itasca 2018.</li></ol></div><div id="graphicVersion">Graphic 107297 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
